Clinical Study
Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial
Table 2
Immunosuppression. Continuous variables are shown as mean ± SD.
| | RD CsA () | ST CsA () |
| Everolimus dose (mg/day) | | | Month 1 | | | Month 6 | | | Everolimus trough concentration (ng/mL) | | | Month 1 | | | Month 6 | | | Cyclosporine dose (mg/kg/day) | | | Month 1 | | | Month 6 | | | Cyclosporine trough concentration (ng/mL) | | | Months 1-2 | | | Month 6 | | | Cyclosporine C2 concentration (ng/mL) | | | Months 1-2 | | | Month 6 | | | Steroid dosea | | | Induction therapy | | | Antithymocyte globulin | 60 (60.6%) | 61 (61.0%) | Interleukin-2 receptor antagonist | 21 (21.2%) | 20 (20.0%) |
|
|
a Mean dose during Months 0–6.
|